Atom Investors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Atom Investors’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-22,362	Closed	-$1.31M	–	694
2023 Q4	$1.31M	Sell	22,362 -2,439	-10%	-$137K	0.23%	145
2023 Q3	$1.08M	Buy	+24,801	New	+$886K	0.25%	122
2021 Q2	–	Sell	-7,896	Closed	-$1.35M	–	358
2021 Q1	$1.35M	Sell	7,896 -3,480	-31%	-$689K	0.23%	95
2020 Q4	$2.5M	Buy	+11,376	New	+$2.46M	0.25%	111

Other funds holding MRTX

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Atom Investors's MRTX Position: Q1 2024 in Review

Atom Investors sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 22,362 shares — an estimated $1.31M sold.

Atom Investors first reported a position in MRTX in Q4 2020 and held it in 4 quarters. The position peaked at $2.5M in Q4 2020. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

Atom Investors reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Atom Investors sold 22,362 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $1.31M.
Atom Investors first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2020 and held it in 4 quarters.
Atom Investors's Mirati Therapeutics, Inc. Common Stock position peaked at $2.5M in Q4 2020.
2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Atom Investors's 13F filing for Q1 2024, filed 15 May 2024.